CL-S03 / Celex Oncology - LARVOL DELTA

Celex Oncology Announce Novel Mechanism in Cancer Care and Attendance at Bio-Europe Spring 2025 (GlobeNewswire) - "The treatment has the potential to control metastatic cancer and block the processes that lead to advanced metastatic disease, which is responsible for approximately 90% of all cancer deaths globally...Celex Oncology is investigating VGSC inhibitors which have the potential to reverse cancer progression and harness the power of bioelectricity, reversing and blocking the processes that lead to advanced and deadly oncological disease...Celex Oncology's CL-S01 and CL-S03 treatments, still in investigational stage, aim to improve both survival and quality of life."

New molecule • Oncology